Abstracts by keywords: prescription
The prescription volume of proton pump inhibitors (PPIs) remains high, although the literature increasingly indicates over-prescribing relative to guideline recommendations. Recent data on the situation in Germany are lacking. The aim of this study was to determine the actual quantity of prescribed and over-the-counter PPIs in Germany. Based on several large IQVIA databases, we show that a total of 2.87 billion PPI tablets were sold between November 2020 and October 2021, with most prescriptions being for the largest pack sizes and strengths. Furthermore, the over-the-counter PPI market grew by an average of 141 million per year over a three-year period. The results of this study suggest the considerable size of the prescription PPI market in Germany, as well as a consistent increase in over-the-counter PPI purchases and a recent rise in prescriptions.
01.10.2024
There has been a clear volume dynamic on the German pharmaceutical market for several years [1]. In addition, factors such as demographic change, medical-technical progress and the increase in outpatient therapy options lead to increasing pharmaceutical expenditure [2]. The legislature took up this progressive development by introducing the Medicines Market Reorganization Act (AMNOG) in 2011. Since then, new medications have been evaluated for their additional benefits. It turns out that a large number of new pharmaceutical products continue to come onto the German market, the additional benefit of which often cannot be proven or for which only a small additional benefit has been identified [3]. In addition, in the period from 2013 to the beginning of 2014, drugs that had already been approved were assessed as part of the AMNOG with regard to their additional benefit (so-called existing market call).1 The only group of active ingredients whose process was completed include the DPP-4 inhibitors (also gliptins).